Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy.

Chest - 1 Feb 2023

Lin Hong T, Wikenheiser-Brokamp Kathryn A, Udstuen Gavin, Jones Blaise, McCormack Francis X

Abstract excerpt

Multiple trials have demonstrated the efficacy of therapies targeting the RAS/MAPK pathway in children with Langerhans cell histiocytosis (LCH), but less is known about the success of this strategy in adults or in LCH that is the result of mutations other than BRAF V600E. A 53-year-old woman who has never smoked presented to our clinic with multisystem, multifocal LCH that resulted from an uncommon BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Histiocytosis, Langerhans-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 36759117
DOI: 10.1016/j.chest.2022.10.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy.PMID 36759117Read ↗

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

MEK Inhibition in the Treatment of Congenital Langerhans Cell Histiocytosis: A Case Report and Review of the LiteratureSemantic proximity Read ↗

Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.Semantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read ↗

Targeted therapy for Langerhans cell histiocytosis with maxillofacial involvement in 20 children.Semantic proximity Read ↗

Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.Semantic proximity Read ↗

Clinical features and treatment of Langerhans cell histiocytosis.Semantic proximity Read ↗

Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children.Semantic proximity Read ↗

Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.Semantic proximity Read ↗

BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.Semantic proximity Read ↗

[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.